GLA
TRDA icon

Great Lakes Advisors’s Entrada Therapeutics TRDA Stock Holding History

Great Lakes Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$283K Sell
38,511
-3,020
-7% -$29K ﹤0.01% 719
2026
Q1 		$524K Sell
41,531
-1,737
-4% -$19.9K ﹤0.01% 588
2025
Q4 		$445K Buy
43,268
+2,239
+5% +$18.9K ﹤0.01% 634
2025
Q3 		$238K Buy
+41,029
New +$240K ﹤0.01% 741

Other funds holding TRDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.47B AUM 42.58% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Great Lakes Advisors's TRDA Position: Q2 2026 in Review

Great Lakes Advisors reduced its Entrada Therapeutics (TRDA) stake by 7.3% in Q2 2026, selling an estimated $29K and leaving 38,511 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #719.

Great Lakes Advisors first reported a position in TRDA in Q3 2025 and has held it in 4 quarters since. The position peaked at $524K in Q1 2026. 42 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Great Lakes Advisors held 38,511 shares of Entrada Therapeutics worth $283K as of Q2 2026.
  • Great Lakes Advisors sold 3,020 Entrada Therapeutics shares in Q2 2026, an estimated $29K.
  • Entrada Therapeutics made up ﹤0.01% of Great Lakes Advisors's portfolio in Q2 2026, its #719 holding.
  • Great Lakes Advisors first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Great Lakes Advisors's Entrada Therapeutics position peaked at $524K in Q1 2026.
  • 42 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.